Canaccord Genuity analyst Matt Bottomley maintained a Buy rating on Green Thumb Industries (GTBIF) today and set a price target of C$20.00. The company’s shares closed last Tuesday at $5.85.
According to TipRanks.com, Bottomley is a 1-star analyst with an average return of -2.8% and a 40.5% success rate. Bottomley covers the Healthcare sector, focusing on stocks such as Harvest Health & Recreation, MedMen Enterprises, and Curaleaf Holdings.
Green Thumb Industries has an analyst consensus of Strong Buy, with a price target consensus of $13.28, which is a 121.3% upside from current levels. In a report issued on March 24, Echelon Wealth Partners also reiterated a Buy rating on the stock with a C$20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.23 and a one-year low of $3.70. Currently, Green Thumb Industries has an average volume of 363.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Green Thumb Industries is headquartered in Chicago, Illinois, and produces and sells medicinal and recreational cannabis through wholesale and retail channels in the United States. It has a presence in 12 states and operates over 30 cannabis stores under the chains Rise and Essence. Green Thumb is focusing its expansion on limited license states with large populations, and it does not currently export into the global medical market due to U.S. federal prohibition. It offers multiple products under a portfolio of cannabis consumer packaged goods brands, including Dr. Solomon’s, Dogwalkers, and Beboe.
Read More on GTBIF:
